TinyGemsBreaks Archive

TuesdayMar 10, 2026 9:20 am

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents TONMYA Data at International Fibromyalgia Congress

Tonix Pharmaceuticals (NASDAQ: TNXP) announced two oral presentations on TONMYA(TM), investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets), at the 8th International Congress on Controversies in Fibromyalgia held March 9-10, 2026, in Krakow, Poland. Post hoc analyses from the Phase 3 RESILIENT trial and pooled data from the RELIEF and RESILIENT studies highlighted rapid pain relief and a favorable benefit-risk profile for TONMYA in adults with fibromyalgia, including statistically significant reductions in pain and a likelihood of clinical benefit nearly four times greater than discontinuation due to adverse events. TONMYA, the first medication approved for fibromyalgia in more than 15…

FridayMar 06, 2026 3:13 pm

TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, which is pioneering proton therapy systems for treating tumors in various types of cancers. “Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with proton therapy,” reads an article discussing the move. “The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors,” said Professor Steve Myers, the former Director of Accelerators and Technology…

FridayMar 06, 2026 9:12 am

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces Peer-Reviewed Publication Highlighting Pharmacokinetics of TONMYA(TM) Sublingual Tablets

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced the publication of a peer-reviewed paper detailing results from randomized open-label studies evaluating the pharmacokinetics of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(TM). Published in Clinical Pharmacology in Drug Development, the journal of the American College of Clinical Pharmacology, the study highlights how TONMYA’s proprietary basifying agent enables rapid transmucosal absorption that bypasses first-pass hepatic metabolism. The formulation, approved by the U.S. Food and Drug Administration on Aug. 15, 2025, for the treatment of fibromyalgia in adults, is designed to increase parent drug exposure during sleep while reducing exposure to…

TuesdayMar 03, 2026 10:10 am

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Approved to Transfer Listing to Nasdaq Global Select Market

Tonix Pharmaceuticals (NASDAQ: TNXP) announced it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading on the higher tier expected to begin at the open of market on March 3, 2026, under the existing ticker symbol “TNXP.” The move reflects the company’s compliance with the Nasdaq Global Select Market’s more stringent financial and corporate governance requirements and is expected to enhance institutional visibility, liquidity and broader market recognition. Management described the uplisting as an important milestone as the company continues to focus on…

MondayMar 02, 2026 9:45 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than 20 years of global leadership experience spanning clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, having led Phase 1–3 programs and supported regulatory approvals in the United States, Europe, China and Japan. She has previously served as chief medical officer at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4…

ThursdayFeb 26, 2026 9:20 am

TinyGemsBreaks – NextPlat Corp (NASDAQ: NXPL) Expands Orbital Satcom Into Five Latin American Markets via Mercado Libre

NextPlat (NASDAQ: NXPL, NXPLW) announced a major expansion of its Orbital Satcom North American operations into five South American markets through the launch of online storefronts on Mercado Libre, the largest e-commerce platform in Latin America. The new sites will serve customers in Mexico, Brazil, Argentina, Chile and Colombia, offering wireless and satellite-based connectivity products operating on commercial satellite networks including Globalstar, Iridium and Inmarsat. The company said the expansion targets growing regional demand for satellite-enabled voice, data, tracking and safety solutions across South America’s approximately 440 million residents, with additional market launches planned in the second quarter of 2026.…

WednesdayFeb 25, 2026 9:00 am

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Appoints Jamie MacLaurin SVP of Sports Business, Secures 68% Supermajority of Veloce

SEGG Media (NASDAQ: SEGG, LTRYW) announced that Jamie MacLaurin, co-founder of Veloce Media Group and CEO of Quadrant, was appointed senior vice president of SEGG’s sports business as the company secured supermajority control of approximately 68% of Veloce’s outstanding equity. SEGG indicated it will extend a global offer to acquire the remaining minority interests to streamline governance and align long-term strategy, with Veloce expected to contribute approximately $20 million in annual revenue beginning in Q1 2026. MacLaurin will continue leading Veloce and Quadrant while identifying broader commercial opportunities across SEGG’s sports portfolio, leveraging Quadrant’s creator-led motorsport brand co-founded with 2025…

TuesdayFeb 24, 2026 10:39 am

TinyGemsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) Featured on Latest TechMediaWire Podcast Episode Released by IBN

Rail Vision (NASDAQ: RVSN) is featured in the latest episode of The TechMediaWire Podcast released by IBN, which delivers updates and executive interviews across the technology sector. During the episode, CEO David BenDavid discussed the company’s AI-based vision systems designed to provide real-time hazard detection and situational awareness for rail operators, highlighting the value of early threat detection in reducing incidents, damage and downtime. BenDavid also emphasized 2026 priorities centered on commercial scaling, converting pilot programs into repeat orders and expanding strategic partnerships, while noting increasing industry urgency around railway safety and growing receptiveness to advanced detection systems. To view the full press release, visit https://ibn.fm/HQB7E About Rail Vision Ltd. Rail…

TuesdayFeb 24, 2026 9:40 am

TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its board of directors, where she will also serve as chair of the company’s Scientific Advisory Committee, subject to approval by Cboe Canada. Dr. Lewis-Hall brings more than 40 years of experience across clinical care, research, academia and senior biopharmaceutical leadership, including more than a decade on Pfizer’s executive leadership team as executive vice president and chief medical officer, as well as leadership roles at Vertex Pharmaceuticals, Bristol…

TuesdayFeb 24, 2026 9:32 am

TinyGemsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) Majority-Owned Quantum Transportation Deploys Transformer-Based Neural Decoder on AWS Cloud

Rail Vision (NASDAQ: RVSN) announced that its majority-owned subsidiary, Quantum Transportation Ltd., successfully implemented its transformer-based neural decoder on the AWS cloud, marking a milestone toward real-world quantum applications in the transportation sector. The deployment follows the recent unveiling of Quantum Transportation’s transformer neural decoder, which outperformed classical quantum error correction algorithms in simulations, and the delivery of its first universal error correction prototype, providing scalable infrastructure to process complex quantum data. The company indicated that the cloud-based implementation enables collaboration with quantum hardware partners and supports direct testing of its code-agnostic decoder on physical quantum systems, with potential long-term applications in railway…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks